Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,
Read more